Famotidine/omeprazole

Drug Profile

Famotidine/omeprazole

Alternative Names: Omeprazole/famotidine; OX-17

Latest Information Update: 26 Feb 2013

Price : $50

At a glance

  • Originator Orexo
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Gastrokinetics; Small molecules; Thiazoles
  • Mechanism of Action Histamine H2 receptor antagonists; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-II/III for Gastro-oesophageal reflux in Europe (PO)
  • 25 Feb 2013 Novartis terminates its licence for famotidine/omeprazole worldwide
  • 09 Feb 2009 Orexo and an undisclosed healthcare company agree to co-develop Famotidine/omeprazole for Gastro-oesophageal reflux
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top